{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-22-000071","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2022-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.710070+00:00","generated_at":"2026-06-23T03:37:58.499432+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Centessa CMO Javad Shahidi departs; Antoine Yver assumes responsibilities effective Oct 14, 2022","bullets":["CMO Javad Shahidi mutually agreed to depart; last day Oct 14, 2022.","Departure not due to any disagreement regarding operations, policies, or practices.","Chairman of Development Antoine Yver (30+ yrs drug dev) assumes all CMO responsibilities effective Oct 14.","Dr. Yver led approvals for 11 drugs including Tagrisso, Lynparza, Enhertu; prior roles at Daiichi Sankyo and AstraZeneca."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-22-000071","json":"https://secwatch.observer/filing/0001847903-22-000071.json","markdown":"https://secwatch.observer/filing/0001847903-22-000071.md","text":"https://secwatch.observer/filing/0001847903-22-000071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790322000071/0001847903-22-000071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790322000071/cnta-20221013.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T03:37:58.499432+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"063a07237d","claim":"Antoine Yver changed role as Chief Medical Officer at Centessa Pharmaceuticals plc.","evidence_excerpt":"Antoine Yver, M.D., M.Sc., Chairman of Development of the Company, will assume all responsibilities currently held by Dr. Shahidi effective October 14, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847903/000184790322000071/0001847903-22-000071-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"assumed responsibilities"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"e1615e7458","claim":"Javad Shahidi departed as Chief Medical Officer at Centessa Pharmaceuticals plc.","evidence_excerpt":"On October 13, 2022, Centessa Pharmaceuticals plc (the “Company”) and Javad Shahidi, M.D., M.Sc., Chief Medical Officer, mutually agreed that Dr. Shahidi will be departing from the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847903/000184790322000071/0001847903-22-000071-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"mutually agreed to depart"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}